Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)

MLA

Kiyotaka Miura, et al. “Osimertinib in Poor Performance Status Patients with T790M-Positive Advanced Non-Small-Cell Lung Cancer after Progression of First- and Second-Generation EGFR-TKI Treatments (NEJ032B).” International Journal of Clinical Oncology, vol. 27, no. 1, Oct. 2021, pp. 112–20. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....83096e34e31b1e0f189ad2972dcda7c1&authtype=sso&custid=ns315887.

APA

Kiyotaka Miura, Ryota Saito, Kensuke Nakazawa, Takeshi Isobe, Ryoichi Honda, Yuki Akazawa, Nobuhiro Kanaji, Susumu Takeuchi, Yukari Tsubata, Kana Watanabe, Satoshi Morita, Kunihiko Kobayashi, Taku Nakagawa, Atsushi Nakamura, Naoki Furuya, Daisuke Jingu, Eiki Ichihara, Atsuto Mouri, Satoshi Ohizumi, … Hiroshige Yoshioka. (2021). Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). International Journal of Clinical Oncology, 27(1), 112–120.

Chicago

Kiyotaka Miura, Ryota Saito, Kensuke Nakazawa, Takeshi Isobe, Ryoichi Honda, Yuki Akazawa, Nobuhiro Kanaji, et al. 2021. “Osimertinib in Poor Performance Status Patients with T790M-Positive Advanced Non-Small-Cell Lung Cancer after Progression of First- and Second-Generation EGFR-TKI Treatments (NEJ032B).” International Journal of Clinical Oncology 27 (1): 112–20. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....83096e34e31b1e0f189ad2972dcda7c1&authtype=sso&custid=ns315887.